Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-021-04036-7
Abstract: Therapeutic approach for NAFLD is limited and there are no approved drugs. Pioglitazone (PGZ), a thiazolidinedione (TZD) that acts via peroxisome proliferator activated receptor gamma (PPAR γ ) is the only agent that has shown… read more here.
Keywords: lep mkyo; mouse models; mice; fatty liver ... See more keywords